CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Ticagrelor with or without Aspirin in High-Risk Patients after PCI
|<<... 7 8 9 10 11 12 13 ...>>|

Original Research2016 Nov 21;37(44):3335-3342.

JOURNAL：Eur Heart J. Article Link

Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry

Sahlén A, Varenhorst C, Lagerqvist B et al. Keywords: ticagrelor versus clopidogre; myocardial infarction; major bleeding; death; stroke, death

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top